VACC Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 Nov 2023 @ 22:00):

Stats
Tagesvolumen	163 052
Durchschnittsvolumen	731 881
Marktkapitalisierung	192.73M
EPS	$0.220 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.45
ATR14	$0.559 (17.75%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Pelletier Nadege	Buy	105 000	Share Option (Right to Buy)
2024-01-02	Griffiths Graham	Buy	96 500	Share Option (Right to Buy)
2024-01-02	Enright William	Buy	443 981	Share Option (Right to Buy)
2024-01-02	Brown Gemma	Buy	193 000	Share Option (Right to Buy)
2023-06-26	Scheeren Joseph	Buy	10 000	Ordinary Shares

INSIDER POWER
41.25
Last 95 transactions
Buy: 18 963 250 \| Sell: 20 685 755

Volumen Korrelation

Lang: 0.07 (neutral)

Kurz: 0.52 (weak)

Signal:(49.914) Neutral

Vaccitech plc Korrelation

10 Am meisten positiv korreliert
SVOK	0.919
PAIC	0.901
FORE	0.872
RDUS	0.87
SVAC	0.858
RMRM	0.857
SPRT	0.835
TLGT	0.834
EPZM	0.829
IVA	0.828

10 Am meisten negativ korreliert
NETE	-0.908
BOCH	-0.876
RAVN	-0.866
AMRB	-0.862
HRMY	-0.852
SBBP	-0.847
MMAC	-0.843
CFMS	-0.835
SFST	-0.829
AEPPZ	-0.827

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Vaccitech plc Korrelation - Währung/Rohstoff

-0.16
( neutral )

0.30
( neutral )

0.00
( neutral )

-0.05
( neutral )

0.33
( neutral )

0.12
( neutral )

Vaccitech plc Finanzdaten

Annual	2022
Umsatz:	$44.70M
Bruttogewinn:	$2.35M (5.26 %)
EPS:	$0.140

FY	2022
Umsatz:	$44.70M
Bruttogewinn:	$2.35M (5.26 %)
EPS:	$0.140

FY	2021
Umsatz:	$268 000
Bruttogewinn:	$268 000 (100.00 %)
EPS:	$-1 067.56

FY	2020
Umsatz:	$4.82M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-371.62

Financial Reports:

No articles found.

Vaccitech plc

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.